Abstract
Background/Aim The potential link between smoking and the susceptibility to Graves’ disease (GD) has been scrutinized in observational studies, yielding inconsistent results. We conducted a Mendelian randomization (MR) analysis to ascertain the causal relationship between smoking behaviors and the risk of GD.
Method The data on smoking behaviors, including smoking initiation and lifetime smoking, were obtained from the published GWAS of individuals of European descent who participated in the GSCAN consortium. The genetic variants associated with Graves’ disease were identified using a GWAS of 458,620 participants of European descent from the UK Biobank.
Results Our results show that smoking initiation was associated with GD [OR= 1.50, 95% CI (1.03,2.18), SE□=□0.199, Pbeta□=□0.031; Cochran’s Q=36.62, p=0.999, I2=0.0%; MR–Eggerintercept= 0.003, p= 0.879], and lifetime smoking [OR□=□3.42, 95% CI (1.56, 7.50), SE□=□0.39, Pbeta<0.01; Cochran’s Q=62.68, p=0.99, I2=0.0%; Eggerintercept=0.012, p=0.49]. All other MR methods, as well as sensitivity analysis results, were consistent in terms of betas and significance levels.
Conclusion Our findings lend support to a causal relationship between smoking behaviors and the risk of Graves’ disease. These observations raise important questions about the role of smoking in the progression of GD. So, further investigation is clinically necessary to clarify the links between smoking and GD, which could inform health policy decisions aimed at reducing the risk of GD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: akbarzadeh.ms{at}gmail.com.
Email: maryam.pourganji92{at}gmail.com
Email: tabashiri309{at}gmail.com.
Email: Sahh.tf{at}gmail.com
Email: mahdisalarabedi{at}gmail.com
Email: dhabibi67{at}gmail.com
Email: aysanmoeinafshar{at}gmail.com
Email: saeidiana{at}chop.edu
Email: ircms{at}yahoo.com
Email: parisaariyahii{at}gmail.com
Email: zarkesh{at}endocrine.ac.ir
Email: hakonarson{at}chop.edu
Email: azizi{at}endocrine.ac.ir.
Email: hedayati47{at}gmail.com.
Data Availability Statement
The original data used are publicly available at https://www.ebi.ac.uk/gwas/. The original contributions presented in the study are included in the article/Supplementary Material. The process of MR analyses and the results are publicly available through the following HTML link: https://akbarzadehms.github.io/SmokinGravesMR/